medicenna.jpg
Medicenna Announces Upcoming Poster Presentations at the AACR Annual Meeting
09 mars 2022 07h00 HE | Medicenna Therapeutics Corp.
TORONTO and HOUSTON, March 09, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...
medicenna.jpg
Medicenna Announces Appointment of Clinical Advisory Board and Dr. Kapil Dhingra as Strategic Advisor
03 mars 2022 07h00 HE | Medicenna Therapeutics Corp.
Medicenna’s Clinical Advisory Board is comprised of thought leaders in immuno-oncology with experience in clinical development of Proleukin® and next generation IL-2 Dr. Dhingra has a track record of...
medicenna.jpg
Medicenna to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
10 févr. 2022 07h00 HE | Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
medicenna.jpg
Medicenna Reports Third Quarter Fiscal 2022 Financial Results and Operational Highlights
09 févr. 2022 07h00 HE | Medicenna Therapeutics Corp.
-- Phase 1/2 ABILITY study of MDNA11 on track with first set of efficacy results from early dose escalation cohorts expected in mid-calendar 2022 -- Preliminary pharmacodynamic data show preferential...
medicenna.jpg
Medicenna to Announce Third Quarter Fiscal 2022 Financial Results and Operational Highlights on Wednesday, February 9, 2022
02 févr. 2022 07h30 HE | Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
medicenna.jpg
Medicenna Announces Formation of its Scientific Advisory Board
31 janv. 2022 07h00 HE | Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
medicenna.jpg
Medicenna Announces Peer-Reviewed Publication of Preclinical Data on MDNA11 in the Journal for ImmunoTherapy of Cancer
26 janv. 2022 07h00 HE | Medicenna Therapeutics Corp.
-- MDNA11 demonstrates a 30-fold increase in affinity for IL-2 receptor beta without binding to IL-2 receptor alpha when compared to recombinant human IL-2 -- MDNA11 was well-tolerated...
medicenna.jpg
Medicenna Announces Management Change and Appoints Experienced Development Advisory Committee
17 janv. 2022 18h00 HE | Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
medicenna.jpg
Medicenna to Participate in Upcoming January Investor Conferences
05 janv. 2022 07h00 HE | Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
medicenna.jpg
Medicenna Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with MDNA11 Treatment in the Phase 1/2 ABILITY Study
22 déc. 2021 08h14 HE | Medicenna Therapeutics Corp.
-- Peak CD8+ T cell (anti-tumor) / Treg (pro-tumor) ratio increased ~2-3 fold over baseline with MDNA11 treatment in the trial’s first two dose escalation cohorts -- MDNA11-induced increases in...